Key takeaways
Rinvoq (upadacitinib) and Cosentyx (secukinumab) are both medications used to treat inflammatory conditions like ankylosing spondylitis and psoriatic arthritis. However, they belong to different medication classes. Rinvoq is a Janus kinase (JAK) inhibitor, while Cosentyx is an interleukin 17 (IL-17) inhibitor. Rinvoq is taken orally, either as a tablet or liquid, and is typically dosed once daily. In contrast, Cosentyx is administered as an injection, usually once a month after initial loading doses. Both medications are only available as brand-name products. Common side effects of Rinvoq include acne and upper respiratory infections, while Cosentyx may cause common cold symptoms and diarrhea. Both medications can increase the risk of infections, but Cosentyx may also worsen inflammatory bowel disease symptoms. Additionally, Rinvoq interacts with grapefruit, while Cosentyx requires caution with latex allergies due to its injection devices.
